Effects of OCTA-guided PDT in Acute CSC

checkorphan
Learn more about:
Central serous chorioretinopathy
Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

Effects of OCTA-guided PDT in Acute CSC

Official Title

Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy

Brief Summary

      OCTA-guided PDT is as safe and effective as ICGA-guided PDT in the treatment of acute central
      serous chorioretinopathy. Or OCTA-guided PDT is more effective than ICGA-guided PDT in the
      treatment of acute central serous chorioretinopathy, safe as well.

Study Type

Interventional

Primary Outcome

Number of patients with subretinal fluid resolution on OCT after PDT of two groups

Secondary Outcome

 Number of patients with leakage point resolution on FFA after PDT of two groups

Condition

Central Serous Chorioretinopathy

Intervention

OCTA-guided Photodynamic therapy

Study Arms / Comparison Groups

 OCTA group
Description:  Patients in this group underwent OCTA-guided half-dose photodynamic therapy.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Procedure

Estimated Enrollment

23

Start Date

September 1, 2017

Completion Date

March 27, 2018

Primary Completion Date

December 1, 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Idiopathic detachment of the neurosensory retina with a focal leak at the level of the
             RPE with FA

          -  Presence of SRF and/or serous pigment epithelial detachment on OCT

          -  Presence of abnormal dilated choroidal vasculature in ICGA

        Exclusion Criteria:

          -  Patients with other ocular conditions commonly associated with SRF, such as choroidal
             neovascularization, polypoidal choroidal vasculopathy (PCV), diabetic retinopathy,
             retinal vascular occlusion, Coat's disease

          -  Any disease that may affect the quality of imaging (quality of OCTA images < 6), such
             as cataract, high myopia or nystagmus

          -  History of ocular surgeries including retinal laser

          -  Pregnancy

          -  Any uncontrolled systemic disease

          -  Any condition rendering patients intolerable to image acquisition

Gender

All

Ages

18 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

Mingwei Zhao, M.D, ,

Location Countries

China

Location Countries

China

Administrative Informations

NCT ID

NCT03497000

Organization ID

Peking UPH

Responsible Party

Principal Investigator

Study Sponsor

Peking University People's Hospital

Collaborators

 National Natural Science Foundation of China

Study Sponsor

Mingwei Zhao, M.D, Study Director, Peking University People's Hospital

Verification Date

April 2018